Closing: 5.00 pm on Thursday 21 December 2023.
Reopening: 9.00 am on Monday 8 January 2024.
We wish you all a merry and safe Christmas and New Year.
To further ensure our BodyShield effectively fulfilled our hygiene requirements in a therapeutic setting, Purifas sponsored a clinical trial that was developed and completed by an independent microbiologist from Macquarie University in Sydney. This trial tested the effectiveness of our BodyShield in reducing bacterial transmission and, in turn, diminishing the risk of illness.
Details of the trial are as follows:
The collected data was then forwarded to a statistician and the following results were deduced:
Control Swab (pre-massage)
For our research and statistically inclined customers only
Although a statistical difference (p-value < 0.05) was shown in the data collected from this clinical trial, the null hypothesis suggests there may be no significant difference between specified populations and that any observed difference could potentially be due to sampling size or experimental error. To overcome this, a power test, which is the probability of rejecting the null hypothesis when in fact it is false, was performed and showed that in order to have 95% power, thereby increasing the reliability of this data, there should be 30 participants in each group.
For this reason, Purifas is currently working with Macquarie University directly to recreate this study with a larger subject group to ensure its accuracy and assist in changing standard practice.
🡠 Back to Research Information View Market Research 🡢
WORLD'S FIRST RESEARCH ― A significant amount of government funding is consistently allocated to research into infection risks and prevention in hospital environments, however, the same can't be said for therapy environments. This lack of research prompted us to commission our own preliminary research into the infection risks associated with therapy beds, with a focus on the transmission of both bacteria and saliva. The results are in and they will shock you!